Spermidine supplementation at 6 mg daily for 13 weeks reversed immune senescence markers in older adults and significantly enhanced vaccine responses, particularly in those who initially failed to mount adequate antibody responses. This pilot study demonstrates that senescence signatures in lymphocytes can predict poor vaccine responsiveness and may be pharmacologically targetable.
Key Points
- Spermidine reversed p16 elevation and mTOR signaling in vaccine non-responders
- Supplementation restored autophagic flux and enhanced spike-specific antibody production
- Senescence markers predicted vaccine failure, enabling stratification of at-risk older adults
Longevity Analysis
Age-related decline in immune competence represents a fundamental constraint on healthspan and resistance to infectious disease. This research identifies immune senescence not as inevitable but as a reversible state linked to impaired cellular recycling and regeneration. By targeting these mechanisms pharmacologically, intervention becomes possible before vaccine failure occurs. The ability to predict which older adults will mount inadequate responses—and then rescue that response through a well-tolerated compound—shifts the paradigm from accepting age-related immunosuppression to strategically addressing its underlying cellular dysfunction. This approach also suggests broader applicability to other age-related defense system failures.
Original published by Wiley Aging Cell, by Ghada Alsaleh, Mohammad Ali, Amir Hossein Kayvanjoo, Feng Liu, Tanaïs Moreau, Sagida Bibi, Lin Luo, Melissa Govender, Miles Carroll, Sebastian J. Hofer, Eisenberg Tobias, Christoph Magnes, Loren Kell, Christopher Chung, Yu Deng, Aneesha Bhandari, Lucy Garner, Thomas Conrad, Liye Chen, Barbara Kronsteiner‐Dobramysl, Susie Dunachie, Owen B. Spiller, Teresa Lambe, Paul Klenerman, Lucy C. Jones, A. Katharina Simon .